 ## Breadcrumb

- [Home](/)
- [Resources &amp; Support](/resources-support)
- [Parkinson's Today Blog](/resources-support/blog)
 
  ## Breadcrumb

- [Home](/)
- [Resources &amp; Support](/resources-support)
- [Parkinson's Today Blog](/resources-support/blog)
 
  

 

   Advancing Research 

#  The "Golden Year" in Parkinson’s: Why Early Clinical Trial Participation Matters 

 Sep 22, 2026 

 

   ## 🧠 What will you learn in this article? 

 This article highlights how the first year after a Parkinson’s diagnosis can be a valuable window for clinical trial participation.

- The “golden year” refers to the first 12 months after a Parkinson’s diagnosis, when symptoms may be mild and medication may not yet be needed.
- Before beginning PD medications, researchers can observe a person’s natural baseline and test treatments that may slow or stop PD progression.
- Greater awareness and early conversations with care team members can help newly diagnosed people join clinical trials sooner.

 

   ![A female patient talking with her doctor who is holding a tablet.](/sites/default/files/styles/no_sizing/public/images/golden-year_0.png?itok=aCjTNhVP)  After a Parkinson’s diagnosis, many people start their journey by learning about treatments to help ensure their best quality of life. But according to experts like Robert Hauser, MD, from the University of South Florida, a [Parkinson’s Foundation Center of Excellence](/living-with-parkinsons/finding-care/global-care-network "Global Care Network"), the initial months after a diagnosis also hold a unique window of opportunity that may go unnoticed by people [newly diagnosed](/living-with-parkinsons/new-to-parkinsons "New to Parkinson's") with Parkinson’s and their care team.

In [Episode 108](/library/podcast/108 "Episode 108: The Golden Year for Testing Disease Modifying Drugs") of the Parkinson’s Foundation podcast *Substantial Matters: Life &amp; Science of Parkinson's*, Dr. Hauser discusses the "golden year," a time prior to starting Parkinson’s medications. This window may hold a key to finding therapies that could change the course of PD.

### What is the “Golden Year”?

The "golden year" refers to the period of about 12 months after diagnosis when a person is more likely to have mild [movement symptoms](/understanding-parkinsons/movement-symptoms "Movement Symptoms") and may not yet need Parkinson’s medications to manage activities of daily life.

Before starting [medications](/living-with-parkinsons/treatment/prescription-medications "Prescription Medications") to manage Parkinson’s symptoms, the brain is at its natural baseline. People who have not started medications are sometimes called treatment naïve. Being treatment naïve gives researchers a window to test disease-modifying therapies — treatments designed to slow, halt or possibly reverse Parkinson's progression.

### Timing Matters

Current [Parkinson's medications](/living-with-parkinsons/treatment/prescription-medications "Prescription Medications") manage movement symptoms such as stiffness and slowness of movement. However, they do not treat symptoms that may appear after many years, such as [cognitive changes](/understanding-parkinsons/non-movement-symptoms/cognitive "Cognitive Changes") or serious balance issues. An important need in Parkinson's research is finding a way to diagnose the disease as early as possible and halt its progression before these long-term symptoms arise.

For a [clinical trial](/living-with-parkinsons/treatment/clinical-trials "Clinical Trials") to test how a new treatment works, researchers must track changes in a person’s PD over time. Entering a trial before daily medication becomes necessary gives researchers the clearest picture of how well the new treatment works. This makes the "golden year" a unique opportunity for both researchers and people with PD.

Despite the importance of trials in the first year after a Parkinson’s diagnosis, finding eligible participants is a hurdle. It remains a challenge because of these factors:

- **Starting medication:** Neurologists often start people with PD on medications right away, making treatment-free baseline observations unavailable.
- **Wait times:** Delays in scheduling appointments with [movement disorder specialists](/living-with-parkinsons/finding-care/building-your-team "Building Your Care Team") can cause newly diagnosed people to miss early trial eligibility.
- **Awareness:** Many health care professionals are unaware of clinical trials for newly diagnosed and treatment naïve people — or how important the golden year is to Parkinson’s research — and do not share trial information with people with PD.

### What can we do?

To make the most of this critical time, collaboration is needed between people with Parkinson’s and their care teams:

- **People with Parkinson’s and families:** If you or a loved one is newly diagnosed and do not feel an immediate need for medication to manage daily activities, ask your PD doctor about clinical trial opportunities for treatment-naïve individuals.
- **Healthcare providers:** Doctors and care teams should discuss clinical trials with their newly diagnosed patients before prescribing PD medications. If symptoms are mild and manageable, allowing time to consider a trial can open doors to groundbreaking research.
- **Improving access:** Some medical centers are working to improve systems to get newly diagnosed people into appointments quickly, so they can explore trial options before starting standard treatment.

 [Explore current clinical trials.](/advancing-research/join-study "Join A Study")

 

 ### What’s Next

Every approved Parkinson’s treatment exists today because people chose to voluntarily participate in clinical research in the past. Raising awareness about research options helps to ensure newly diagnosed people know what's available and to decide if research participation is the right choice for them.

**Whether you are newly diagnosed or familiar with Parkinson’s, explore opportunities to get involved with PD research today.** [Explore current studies now.](/advancing-research/join-study "Join A Study")

  ##  Related Materials 

   Fact Sheets 

###  [ My Parent Has Parkinson's. What Does It Mean? ](/library/fact-sheets/parent-has-parkinsons) 

 

 [Read Now](/library/fact-sheets/parent-has-parkinsons) 

 Fact Sheets 

###  [ Managing "Off" Time in Parkinson's ](/library/fact-sheets/managing-off-time) 

 

 [Read Now](/library/fact-sheets/managing-off-time) 

 Fact Sheets 

###  [ Medications for Non-motor Symptoms ](/library/fact-sheets/medications-nonmotor-symptoms) 

 

 [Read Now](/library/fact-sheets/medications-nonmotor-symptoms) 

 

  ##  Related Blog Posts 

   ![team of researchers at the University of Florida's Parkinson’s Foundation Research Center ](/sites/default/files/styles/500x360/public/images/research-center-profile-3_0.png?h=ed9ce7df&itok=dcPo-_oo)  

 Advancing Research 

###  [ From Gut Instincts to Research Breakthroughs: How the University of Florida Connected Alpha-synuclein, Inflammatory Bowel Disease and Parkinson’s ](/blog/research/university-of-florida) 

 

  READ NOW  

 ![Brittany Krzyzanowski headshot](/sites/default/files/styles/500x360/public/images/mtr-brittany-krzyzanowski-preview.jpg?h=9105c3fe&itok=eC-nucBL)  

 Advancing Research 

###  [ From Golf Courses to Industrial Solvents: Meet the Researcher Investigating Parkinson's Risk ](/blog/research/meet-brittany-krzyzanowski) 

 

  READ NOW  

 ![Woman using laptop](/sites/default/files/styles/500x360/public/images/eb-3-ai-blog-hero.jpg?h=ed9ce7df&itok=yCB2aRv_)  

 Advancing Research 

###  [ Artificial Intelligence is Unlocking New Possibilities for Parkinson’s Care ](/blog/research/artificial-intelligence-parkinsons-care) 

 

  READ NOW  

 

 [VIEW ALL BLOGS](/resources-support/blog) 

  

 ###  Listen to our Podcast 

 New episodes are released every month! Subscribe today for the latest in Parkinson’s research and treatments.

 [LEARN MORE](/resources-support/online-education/podcast) 

 

 

 

 - Share on Facebook
- Share on X
- Share on LinkedIn